All News

hands.stiff2_.jpg

More Noninflammatory Pain in Difficult to Treat RA

Jack Cush, MD

A Canadian cohort of difficult-to-treat rheumatoid arthritis (D2T RA) patients shows significantly more non-inflammatory pain in D2T RA compared to patients responding to b/tsDMARDs.

Read Article
cost.healthcare.jpg

The Burden of Rheumatoid Arthritis (2018–2020)

Jack Cush, MD

A recent study that quantified the economic and humanistic burden of rheumatoid arthritis (RA) in the USA showed significantly higher health care expenditures, particularly medication costs, and suboptimal quality of life in RA.

Read Article
lung,cancer,blue,mass

Lung Cancer in Rheumatoid Arthritis and Interstitial Lung Disease

Jack Cush, MD

A matched cohort study from the Veterans Health Administration shows that rheumatoid arthritis patients have a >50% increased risk of lung cancer, and a 3-fold higher risk of lung cancer in RA-interstitial lung disease (ILD).

Read Article
RheumNow Podcast square

Depends on Where You’re Looking (8.9.2024)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from RheumNow.com this week.

Read Article
overdose.narcotic.jpg

Prescription Painkiller Misuse in Chronic Pain Patients

EurekAlert!

A new scientific review of 148 studies enrolling over 4.3 million adult chronic pain patients treated with prescription opioid painkillers has found that nearly one in ten patients experiences opioid dependence or opioid use disorder and nearly one in three shows symptoms of dependence and opioid use disorder.

Read Article
RA,polyarticular,black,rheumatoid

Economic, Personal Burden of RA: Maybe Not So Bad?

MedPage Today

Data from a major federal survey indicate that people with rheumatoid arthritis (RA) don't pay massively more for healthcare than other folks, nor is their risk for functional deficits tremendously greater, researchers found.

Read Article
T2T.RA2_.jpg

Barriers to Treat-to-Target in Rheumatoid Arthritis

Jack Cush, MD

A systematic and scoping literature examined the Treat-to-target (T2T) approach to rheumatoid arthritis (RA), noting its implementation is suboptimal and finding many barriers to implementation.

Read Article
RheumNow Podcast square

Lead with Lupus (8.2.2024)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com - leading with lupus because everyone wants to know about lupus!

Read Article
Breast CA (BC) & TNFi - study of 2 cohorts (Optum commercial * SEER/Medicare) found that 17% & 16% of BC pts received TNFi. 1 yr overall survival was no different +/- TNFi (HR= 0.77 & 0.84); but BC survival better on TNFi (HR 0.28; 0.08–0.98) vs csDMARDs. https://t.co/cGqT80rGTR https://t.co/n7i5VNFkVT

Links:

Dr. John Cush RheumNow ( View Tweet)
Review of Inflammatory vs non-inflammatory pain in RA - Pain may be more than inflammation - Residual plain is a problem - Consider damage vs FM - Central vs. Neuogenic pain https://t.co/JUgc5IsgMq https://t.co/CRekJsAP04

Links:

Dr. John Cush RheumNow ( View Tweet)
Full Read Overview of the safety of bDMARDs/tsDMARDS - contraindications, precautions, & boxed warnings for treatment of RA, PsA, SpA, JIA - safety checklist for a class of drugs you use and diseases you treat https://t.co/5chrS3sW8i https://t.co/twSv4Zs9r3

Links:

Dr. John Cush RheumNow ( View Tweet)
Exploratory study of 22 RA pts w/ mod/severe periodontitis and RA. After periodontal Tx, only pts w/ severe (not moderate) periodontitis had significant reduction in DAS28 and CCP2 levels. Use periodontal Tx in RA management & T2T strategy? https://t.co/X7oXByzTnX https://t.co/b0vwTp4tfd

Links:

Dr. John Cush RheumNow ( View Tweet)
Barriers to Treat-to-Target in Rheumatoid Arthritis A systematic and scoping literature examined the Treat-to-target (T2T) approach to rheumatoid arthritis (RA), noting its implementation is suboptimal and finding many barriers to implementation. https://t.co/CMEd62BfU0 https://t.co/YHQ408No4S

Links:

Dr. John Cush RheumNow ( View Tweet)
Economic, Personal Burden of RA: Maybe Not So Bad? Data from a major federal survey indicate that people with RA don't pay massively more for healthcare than other folks, nor is their risk for functional deficits tremendously greater, researchers found. https://t.co/ZFw7KZ0Wsb https://t.co/bO02YbzWvb

Links:

Dr. John Cush RheumNow ( View Tweet)
PROs: Their Proper Place https://t.co/gYjrRcqLy4 https://t.co/QJ9DYp8JuV

Links:

Dr. John Cush RheumNow ( View Tweet)
N Zealand Rheum Assn audit of 355 new seropositive pts referred, saw 65% starting DMARDs w/in 6 wks. DMARD starts were linked rurality & the # of rheumatologists. If there was 1 Rheum FTE/100,000 population, 80% were on DMARDs <=6wks https://t.co/8OvniRQt1I https://t.co/TsgegOJ9ZG

Links:

Dr. John Cush RheumNow ( View Tweet)
Calif Cohort of 19340 rheumatic pts, finds Cardiovascular events (CVE) in 1.4% & antiphospholipid syndr in 5.5%. CVE increased risk of adverse pregnancy outcomes (>50%), including Sm for Gestational age (aRRs 1.2-1.5), Premature birth (aRR 1.6) https://t.co/9lxzrOVEks https://t.co/Jcm7tH61cv

Links:

Dr. John Cush RheumNow ( View Tweet)
Systematic review: RX of macrophage activation syndr (MAS), included 57 reports, 1148 MAS pts (889 sJIA, 137 SLE). Most effective was high-dose GCs, IL-1 (83%) & IFNγ (93%) inhibitors, especially in sJIA-MAS. Also Ciclosporin, etoposide, Ruxolitinib https://t.co/4EnMOnlcYl https://t.co/PQnAZLvVwq

Links:

Dr. John Cush RheumNow ( View Tweet)
Full Read Overview of the safety of bDMARDs/tsDMARDS - contraindications, precautions, & boxed warnings for treatment of RA, PsA, SpA, JIA - safety checklist for a class of drugs you use and diseases you treat https://t.co/TIdCtJjF21 https://t.co/UE0nGbESDB

Links:

Dr. John Cush RheumNow ( View Tweet)
Medical literature review of suggests low vitamin D status is common in Rheumatic pts. & low vit D levels linked to loss of muscle strength, MSK pain, sarcopenia & falls (esp in IIM, PMR, SLE, RA, SSc) (BUT DOES REPLACING VITAMIN D FIX THESE PROBLEMS???) https://t.co/30IiKj7l4d https://t.co/ydU6FQMTi5

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×